Portolan Capital Management’s Myriad Genetics MYGN Stock Holding History

Portolan Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,163,400	Closed	-$6.18M	–	142
2025 Q2	$6.18M	Buy	1,163,400 +613,478	+112%	+$3.62M	0.39%	75
2025 Q1	$4.88M	Buy	+549,922	New	+$6.6M	0.37%	76
2024 Q4	–	Sell	-179,634	Closed	-$4.92M	–	156
2024 Q3	$4.92M	Buy	+179,634	New	+$4.86M	0.36%	86
2019 Q2	–	Sell	-125,532	Closed	-$4.17M	–	92
2019 Q1	$4.17M	Buy	+125,532	New	+$3.82M	0.43%	72
2016 Q4	–	Sell	-277,294	Closed	-$5.71M	–	131
2016 Q3	$5.71M	Buy	277,294 +93,729	+51%	+$2.38M	0.78%	50
2016 Q2	$5.62M	Sell	183,565 -18,007	-9%	-$626K	0.81%	46
2016 Q1	$7.54M	Buy	+201,572	New	+$7.6M	1.01%	33
2015 Q2	–	Sell	-95,983	Closed	-$3.4M	–	124
2015 Q1	$3.4M	Buy	95,983 +20,360	+27%	+$729K	0.62%	62
2014 Q4	$2.58M	Buy	+75,623	New	+$2.68M	0.52%	77

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Portolan Capital Management's MYGN Position: Q3 2025 in Review

Portolan Capital Management sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 1,163,400 shares — an estimated $6.18M sold.

Portolan Capital Management first reported a position in MYGN in Q4 2014 and held it in 9 quarters. The position peaked at $7.54M in Q1 2016. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

Portolan Capital Management reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
Portolan Capital Management sold 1,163,400 Myriad Genetics shares in Q3 2025, an estimated $6.18M.
Portolan Capital Management first reported a position in Myriad Genetics in Q4 2014 and held it in 9 quarters.
Portolan Capital Management's Myriad Genetics position peaked at $7.54M in Q1 2016.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Portolan Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.